Clinician and Family Caregiver Perspectives on Deprescribing Chronic Disease Medications in Older Nursing Home Residents Near the End of Life
ConclusionsFindings suggest a need for efforts to encourage communication with and education for family caregivers of residents with LLE about deprescribing, and to foster better collaboration among clinicians in CLC and non-CLC settings. (Source: Drugs and Aging)
Source: Drugs and Aging - April 4, 2024 Category: Geriatrics Source Type: research
Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation
AbstractPurpose of ReviewTargeting traditional cardiovascular risk factors is effective in reducing recurrent cardiovascular events, yet the presence of residual cardiovascular risk due to underlying systemic inflammation is a largely unaddressed opportunity. This review aims to comprehensively assess the evolving role of colchicine as a therapeutic approach targeting residual inflammatory risk in the context of those with coronary artery disease (CAD).Recent FindingsInflammation plays a significant role in promoting atherosclerosis, and targeting anti-inflammatory pathways has the potential to decrease cardiovascular even...
Source: Current Cardiology Reports - April 4, 2024 Category: Cardiology Source Type: research
Pharmacist optimization of lipid therapy in patients with peripheral vascular disease
CONCLUSION: The addition of a pharmacist consult led to an increase in the percentage of patients discharged on a high-intensity statin and an increase in overall statin intensification.PMID:38567808 | DOI:10.1093/ajhp/zxae097 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - April 3, 2024 Category: Drugs & Pharmacology Authors: Mary-Ashlyn Tucker Andrew Meyer Michael Bitonti Megan Supple Brandon Cain Source Type: research
Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study
In conclusion, our study suggests that SSA may serve as a therapeutic agent for addressing the metabolic complications associated with obesity. This potential therapeutic effect is attributed to the suppression of inflammatory cytokines and the upregulation of FGF21 and ATG7.PMID:38569867 | DOI:10.1248/cpb.c23-00782 (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - April 3, 2024 Category: Drugs & Pharmacology Authors: Min-Seong Lee Ji-Won Noh Byung-Cheol Lee Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Atherosclerosis)
Source: Atherosclerosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Pharmacist optimization of lipid therapy in patients with peripheral vascular disease
CONCLUSION: The addition of a pharmacist consult led to an increase in the percentage of patients discharged on a high-intensity statin and an increase in overall statin intensification.PMID:38567808 | DOI:10.1093/ajhp/zxae097 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - April 3, 2024 Category: Drugs & Pharmacology Authors: Mary-Ashlyn Tucker Andrew Meyer Michael Bitonti Megan Supple Brandon Cain Source Type: research
Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study
In conclusion, our study suggests that SSA may serve as a therapeutic agent for addressing the metabolic complications associated with obesity. This potential therapeutic effect is attributed to the suppression of inflammatory cytokines and the upregulation of FGF21 and ATG7.PMID:38569867 | DOI:10.1248/cpb.c23-00782 (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - April 3, 2024 Category: Drugs & Pharmacology Authors: Min-Seong Lee Ji-Won Noh Byung-Cheol Lee Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study
In conclusion, our study suggests that SSA may serve as a therapeutic agent for addressing the metabolic complications associated with obesity. This potential therapeutic effect is attributed to the suppression of inflammatory cytokines and the upregulation of FGF21 and ATG7.PMID:38569867 | DOI:10.1248/cpb.c23-00782 (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - April 3, 2024 Category: Drugs & Pharmacology Authors: Min-Seong Lee Ji-Won Noh Byung-Cheol Lee Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study
In conclusion, our study suggests that SSA may serve as a therapeutic agent for addressing the metabolic complications associated with obesity. This potential therapeutic effect is attributed to the suppression of inflammatory cytokines and the upregulation of FGF21 and ATG7.PMID:38569867 | DOI:10.1248/cpb.c23-00782 (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - April 3, 2024 Category: Drugs & Pharmacology Authors: Min-Seong Lee Ji-Won Noh Byung-Cheol Lee Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Effects of Saikosaponin-A on Insulin Resistance in Obesity: Computational and Animal Experimental Study
In conclusion, our study suggests that SSA may serve as a therapeutic agent for addressing the metabolic complications associated with obesity. This potential therapeutic effect is attributed to the suppression of inflammatory cytokines and the upregulation of FGF21 and ATG7.PMID:38569867 | DOI:10.1248/cpb.c23-00782 (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - April 3, 2024 Category: Drugs & Pharmacology Authors: Min-Seong Lee Ji-Won Noh Byung-Cheol Lee Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
